Meta-Regression of Herpes Zoster Incidence Worldwide.
Adults
Epidemiology
Global
Herpes zoster
Incidence
Meta-analysis
Meta-regression
Review
Shingles
Vaccination
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
10
09
2021
accepted:
11
11
2021
pubmed:
8
12
2021
medline:
8
12
2021
entrez:
7
12
2021
Statut:
ppublish
Résumé
Many studies have been conducted worldwide to estimate herpes zoster (HZ) incidence rates. We synthesized studies of HZ incidence rates in the general population using meta-analysis models. A random effects meta-analysis was conducted to estimate HZ incidence from a published worldwide systematic literature review (SLR) including only individuals aged 50 years and older. Meta-regression was used to explore whether variability in incidence rates could be explained by a combination of study-specific characteristics including age, gender, continent and year of study data. The impact of adding additional covariates-case detection method (general practitioner surveillance, healthcare database, sentinel network, etc.), case definition (medical record-based, self-reported), study design (retrospective passive surveillance, retrospective active surveillance, etc.), incidence type (cumulative incidence/1000 persons or incidence rate/1000 person-years), patient type (outpatients or in- and out-patients) and latitude to the base model-was also assessed. Sixty-one records from 59 studies were included in the analysis: 25, 20, 11 and 5 from Europe, North America, Asia and Oceania, respectively. There was variation in study methodology and outcomes. Heterogeneity of incidence rates was greatest among studies conducted in Asia. Meta-analysis showed that incidence increased with age, was lower in males compared to females, tended to be lower in Europe and North America compared to Asia and Oceania and increased with year of study data. The data-driven meta-regression model included continent, year of study data, gender, age and an age × gender interaction term. The difference in incidence between males and females was greater in younger ages (e.g., 50-59) compared to older age groups (e.g., 80+). None of the additional covariates contributed significantly to the model. Incidence rates were shown to vary by age, gender, continent and year of study data.
Identifiants
pubmed: 34874546
doi: 10.1007/s40121-021-00567-8
pii: 10.1007/s40121-021-00567-8
pmc: PMC8650523
doi:
Types de publication
Journal Article
Langues
eng
Pagination
389-403Informations de copyright
© 2021. The Author(s).
Références
Mizukami A, Sato K, Adachi K, et al. Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Japanese adults aged 60 years or older: results from a prospective, observational cohort study. Clin Drug Investig. 2018;38(1):29–37.
doi: 10.1007/s40261-017-0581-5
Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.
pubmed: 18528318
Centers for Disease Control and Prevention. Shingles (Herpes Zoster). 2018. https://www.cdc.gov/shingles/about/index.html . Accessed July 12, 2021
Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):30.
doi: 10.1186/s12877-017-0420-9
Kawai K, Yawn BP, Wollan P, Harpaz R. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis. 2016;63(2):221–6.
doi: 10.1093/cid/ciw296
Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.
doi: 10.1136/bmjopen-2014-004833
Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806–21.
doi: 10.1016/j.mayocp.2017.10.009
van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17(6):1714–32.
doi: 10.1080/21645515.2020.1847582
Terlinden A, Varghese L, Curran D. Meta-regression on European zoster incidence. Value Health. 2014;17(7):A666–7.
doi: 10.1016/j.jval.2014.08.2459
Toyama N, Shiraki K, Members of the Society of the Miyazaki Prefecture D. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol. 2009;81(12):2053–8.
doi: 10.1002/jmv.21599
Welton NJ, Sutton AJ, Cooper N, Abrams KR, Ades AE. Evidence synthesis for decision making in healthcare. Sons JW. 2012.
van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21(4):589–624.
doi: 10.1002/sim.1040
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions, version 5.0.0. 2008. www.cochrane-handbook.org . Accessed Aug 26, 2021
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
doi: 10.1136/bmj.b2700
Moher D, Liberati A, Tetzlaff J, Altman DG, for the Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
doi: 10.1371/journal.pmed.1000097
Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53.
doi: 10.1111/j.1525-1497.2005.0150.x
Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.
doi: 10.1371/journal.pmed.1001420
Schiffner-Rohe J, Jow S, Lilie HM, Köster I, Schubert I. Herpes zoster in Germany. A retrospective analyse of SHL data. MMW Fortschr Med. 2010;151(Suppl 4):193–7.
pubmed: 21595148
Suaya JA, Chen S-Y, Li Q, Burstin SJ, Levin MJ. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. Open Forum Infect Dis. 2014;1(2):ofu049.
doi: 10.1093/ofid/ofu049
Opstelten W, Van Essen GA, Schellevis F, Verheij TJM, Moons KGM. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol. 2006;16(9):692–5.
doi: 10.1016/j.annepidem.2005.12.002
Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJM, Stalman WAB, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract. 2002;19(5):471–5.
doi: 10.1093/fampra/19.5.471
Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect. 2015;70(2):178–86.
doi: 10.1016/j.jinf.2014.08.018
Jih J-S, Yi-Ju C, Lin M-W, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Adv Dermatol Venereol. 2009;89(6):612–6.
doi: 10.2340/00015555-0729
Rimseliene G, Vainio K, Gibory M, Salamanca BV, Flem E. Varicella-zoster virus susceptibility and primary healthcare consultations in Norway. BMC Infect Dis. 2016;16(1):254.
doi: 10.1186/s12879-016-1581-4
Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.
doi: 10.18637/jss.v036.i03
Burnham KP, Anderson DR. Model selection and multimodel inference: a practical information-theoretic approach, 2nd ed. Springer; 2002.
Cook RD, Weisberg S. Residuals and influence in regression. Hall LCa; 1982.
Di Legami V, Gianino MM, Atti MCD, et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007;25(43):7598–604.
doi: 10.1016/j.vaccine.2007.07.049
Sundström K, Weibull CE, Söderberg-Löfdal K, Bergström T, Sparén P, Arnheim-Dahlström L. Incidence of herpes zoster and associated events including stroke—a population-based cohort study. BMC Infect Dis. 2015;15(1):488.
doi: 10.1186/s12879-015-1170-y
Krishnarajah G, Carroll C, Priest J, Arondekar B, Burstin S, Levin M. Burden of vaccine-preventable disease in adult Medicaid and commercially insured populations. Hum Vaccin Immunother. 2014;10(8):2460–7.
doi: 10.4161/hv.29303
Zhu Q, Zheng H, Qu H, et al. Epidemiology of herpes zoster among adults aged 50 and above in Guangdong. China Hum Vaccin Immunother. 2015;11(8):2113–8.
doi: 10.1080/21645515.2015.1016672
Li Y, An Z, Yin D, et al. Disease burden due to herpes zoster among population aged ≥ 50 years old in China: a community based retrospective survey. PLoS ONE. 2016;11(4):e0152660.
doi: 10.1371/journal.pone.0152660
Lu L, Suo L, Li J, Pang X. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China. Hum Vaccin Immunother. 2018;14(11):2632–5.
pubmed: 30059639
pmcid: 6314398
Imafuku S, Matsuki T, Mizukami A, et al. Burden of herpes zoster in the Japanese population with immunocompromised/chronic disease conditions: results from a cohort study claims database from 2005–2014. Dermatology and Therapy. 2019;9(1):117–33.
doi: 10.1007/s13555-018-0268-8
Takao Y, Miyazaki Y, Okeda M, et al. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study. J Epidemiol. 2015;25(10):617–25.
doi: 10.2188/jea.JE20140210
Kim YJ, Lee CN, Lim C-Y, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. J Korean Med Sci. 2014;29(12):1706–10.
doi: 10.3346/jkms.2014.29.12.1706
Liu B, Heywood AE, Reekie J, et al. Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study. Epidemiol Infect. 2015;143(13):2871–81.
doi: 10.1017/S0950268814003653
Reid JS, Ah Wong B. Herpes zoster (shingles) at a large New Zealand general practice: incidence over 5 years. N Zeal Med J [Internet]. 2014; 127(1407):56–60. http://europepmc.org/abstract/MED/25530332 .
Harrell FE, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985;69(10):1071–7.
pubmed: 4042087
Willer DO, Oostvogels L, Cunningham AL, et al. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019;37(43):6262–7.
doi: 10.1016/j.vaccine.2019.09.028
Daniel Mullins C, Onwudiwe NC, Branco de Araújo GT, et al. Guidance Document: Global Pharmacoeconomic Model Adaption Strategies. Value Health Reg Issues. 2014;5:7–13.
United Nations Department of Economic and Social Affairs. World population prospects, Standard projections. 2019. https://population.un.org/wpp/Download/Standard/Population/ . Accessed Aug 26, 2021
National Institute on Aging. Why population aging matters: a global perspective. 2017. WPAM.pdf (nih.gov). Accessed Aug 26, 2021
Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037–45.
doi: 10.1016/j.vaccine.2018.07.005